602 related articles for article (PubMed ID: 30876964)
1. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
[TBL] [Abstract][Full Text] [Related]
2. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
[TBL] [Abstract][Full Text] [Related]
3. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.
Borren NZ; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024
[TBL] [Abstract][Full Text] [Related]
4. Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis.
Katibian DJ; Solitano V; Polk DB; Nguyen T; Ma C; Syal G; Kobayashi T; Hibi T; Buhl S; Ainsworth MA; Jairath V; Singh S
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):22-33.e6. PubMed ID: 37716619
[TBL] [Abstract][Full Text] [Related]
5. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
Singh S; George J; Boland BS; Vande Casteele N; Sandborn WJ
J Crohns Colitis; 2018 May; 12(6):635-643. PubMed ID: 29370397
[TBL] [Abstract][Full Text] [Related]
6. Table: safety of drugs for IBD in pregnancy.
Med Lett Drugs Ther; 2018 Jul; 60(1550):e116. PubMed ID: 30036355
[No Abstract] [Full Text] [Related]
7. Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease.
Yiu TH; Ko Y; Pudipeddi A; Natale P; Leong RW
Aliment Pharmacol Ther; 2024 Jun; 59(11):1312-1334. PubMed ID: 38651771
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis comparing the efficacy and adverse events of biologics and thiopurines for Crohn's Disease after surgery for ulcerative colitis.
Yadav A; Kurada S; Foromera J; Falchuk KR; Feuerstein JD
Dig Liver Dis; 2018 Oct; 50(10):1004-1011. PubMed ID: 29903546
[TBL] [Abstract][Full Text] [Related]
9. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study.
Khan N; Patel D; Trivedi C; Shah Y; Lichtenstein G; Lewis J; Yang YX
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1919-1927.e3. PubMed ID: 29309905
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated With Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Shukla T; Singh S; Tandon P; McCurdy JD
J Clin Gastroenterol; 2017; 51(5):394-401. PubMed ID: 27875356
[TBL] [Abstract][Full Text] [Related]
11. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
Kirchgesner J; Lemaitre M; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
Gastroenterology; 2018 Aug; 155(2):337-346.e10. PubMed ID: 29655835
[TBL] [Abstract][Full Text] [Related]
12. Combination Immunosuppression in IBD.
Bots S; Gecse K; Barclay M; D'Haens G
Inflamm Bowel Dis; 2018 Feb; 24(3):539-545. PubMed ID: 29462391
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
[TBL] [Abstract][Full Text] [Related]
14. Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis.
Shah ED; Farida JP; Siegel CA; Chong K; Melmed GY
Inflamm Bowel Dis; 2017 Apr; 23(4):570-577. PubMed ID: 28230558
[TBL] [Abstract][Full Text] [Related]
15. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
16. Biologic drugs for inflammatory bowel disease.
Yanai S; Matsumoto T
Nihon Rinsho; 2017 Mar; 75(3):403-407. PubMed ID: 30566782
[TBL] [Abstract][Full Text] [Related]
17. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
18. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
